News | April 14, 2010

PET Imaging Agent Identifies Patients with Alzheimers

April 14, 2010 - Researchers found a new amyloid imaging agent for positron emission tomography (PET) to be efficacious in assigning patients with clinically probable Alzheimer's disease (AD) or amnestic mild cognitive impairment (MCI).
The multicenter phase II trial, Primary Outcome Analysis of the Multicentre Phase II Trial of 18F-Flutemetamol, a Pittsburgh Compound B Derivative for In Vivo Beta Amyloid Imaging, focused on 18F-Flutemetamol, a Pittsburgh compound B derivative for in vivo beta amyloid imaging. Primary outcome analysis found the agent used with PET identified patients likely to have AD or amnestic MCI. Results also showed healthy controls (HC) were at a raised versus normal uptake category.
The viability of the agent, 18F-flutemetamol PET, could augment the impact of beta amyloid imaging on research and clinical practice since its use does not require an on-site cyclotron.
In the trial, which GE Healthcare supported, there were 27 patients with early-stage AD, 20 with MCI. Fifteen had HC above and 10 below 55 years. 20 of the AD and 20 of the MCI cases also underwent a 11C-PIB PET. Five central independent readers blinded to the clinical diagnosis assigned the 18F-flutemetamol scans to either raised or normal uptake categories in a binary way on the basis of visual assessment. As a primary outcome, the researchers used clinical diagnosis as SOT to calculate sensitivity and specificity of visual assessment of AD and HC scans. They also determined concordance between visual assignment and assignment based on standardized uptake value ratios in a composite cortical region (SUVRcomp).
They found the visual assessment assigned 25/27 scans from the AD group to the raised category, 1/15 scans from the elderly HC, and 9/20 scans from the MCI group. Sensitivity and specificity with clinical diagnosis as SOT (AD vs HC) was 92.6 percent and 96 percent, respectively. The correlation coefficient between 18F flutemetamol SUVRcomp and 11C-PIB SUVRcomp was 0.94.
The researchers concluded the study met their primary outcome and supports a role for 18F-flutemetamol PET as a potential biomarker for AD-related amyloidosis.
The investigators will present the results from the study on April 16 at the 62nd American Academy of Neurology in Toronto, Canada.
For more information: www.aan.com/go/am10

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...